Biologic Therapeutic Discovery, Amgen Research, South San Francisco, California, United States of America.
PLoS One. 2023 Jun 2;18(6):e0285971. doi: 10.1371/journal.pone.0285971. eCollection 2023.
Antibody-based therapeutics and recombinant protein reagents are often produced in mammalian expression systems, which provide human-like post-translational modifications. Among the available mammalian cell lines used for recombinant protein expression, Chinese hamster ovary (CHO)-derived suspension cells are generally utilized because they are easy to culture and tend to produce proteins in high yield. However, some proteins purified from CHO cell overexpression suffer from clipping and display undesired non-human post translational modifications (PTMs). In addition, CHO cell lines are often not suitable for producing proteins with many glycosylation motifs for structural biology studies, as N-linked glycosylation of proteins poses challenges for structure determination by X-ray crystallography. Hence, alternative and complementary cell lines are required to address these issues. Here, we present a robust method for expressing proteins in human embryonic kidney 293 (HEK293)-derived stable pools, leading to recombinant protein products with much less clipped species compared to those expressed in CHO cells and with higher yield compared to those expressed in transiently-transfected HEK293 cells. Importantly, the stable pool generation protocol is also applicable to HEK293S GnTI- (N-acetylglucosaminyltransferase I-negative) and Expi293F GnTI- suspension cells, facilitating production of high yields of proteins with less complex glycans for use in structural biology projects. Compared to HEK293S GnTI- stable pools, Expi293F GnTI- stable pools consistently produce proteins with similar or higher expression levels. HEK293-derived stable pools can lead to a significant cost reduction and greatly promote the production of high-quality proteins for diverse research projects.
抗体类治疗药物和重组蛋白试剂通常在哺乳动物表达系统中生产,该系统可提供类似人类的翻译后修饰。在用于重组蛋白表达的可用哺乳动物细胞系中,中国仓鼠卵巢(CHO)衍生的悬浮细胞通常被利用,因为它们易于培养并且往往能够高产蛋白。然而,从 CHO 细胞过表达中纯化的一些蛋白会受到剪辑,并表现出不理想的非人类翻译后修饰(PTM)。此外,CHO 细胞系通常不适合用于生产具有许多糖基化模体的蛋白进行结构生物学研究,因为蛋白的 N-连接糖基化对 X 射线晶体学结构测定提出了挑战。因此,需要替代和互补的细胞系来解决这些问题。在这里,我们提出了一种在人胚肾 293(HEK293)衍生的稳定池表达蛋白的稳健方法,与在 CHO 细胞中表达的蛋白相比,该方法产生的重组蛋白产物的剪接种类要少得多,与瞬时转染的 HEK293 细胞相比,产量更高。重要的是,稳定池生成方案也适用于 HEK293S GnTI-(N-乙酰氨基葡萄糖转移酶 I 阴性)和 Expi293F GnTI-悬浮细胞,有利于生产用于结构生物学项目的具有较少复杂聚糖的高产量蛋白。与 HEK293S GnTI-稳定池相比,Expi293F GnTI-稳定池始终产生具有相似或更高表达水平的蛋白。HEK293 衍生的稳定池可显著降低成本,并极大地促进了各种研究项目的高质量蛋白生产。